GRFS

Grifols SA

Add to Watchlist

Advanced Chart

10.045

+0.105(1.056%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

10.080

Open

9.990

VWAP

10.04

Vol

170.01K

Mkt Cap

6.83B

Low

9.990

Amount

1.71M

EV/EBITDA(TTM)

11.46

Total Shares

679.09M

19.15B

EV/OCF(TTM)

15.92

P/S(TTM)

1.15

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

1.90B

+4.36%

1.91B

+6.27%

2.07B

+4.55%

Estimates Revision

The market is revising Downward the revenue expectations for Grifols, S.A. (GRFS) for FY2025, with the revenue forecasts being adjusted by -0.75% over the past three months. During the same period, the stock price has changed by 39.32%.

Revenue Estimates for FY2025

Revise Downward

-0.75%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.43%

In Past 3 Month

Stock Price

Go Up

+39.32%

In Past 3 Month

1 Analyst Rating

2.54% Upside

Wall Street analysts forecast GRFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRFS is 10.30 USD with a low forecast of 10.30 USD and a high forecast of 10.30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

2.54% Upside

Current: 10.045

Low

10.30

Averages

10.30

High

10.30

2.54% Upside

Current: 10.045

Low

10.30

Averages

10.30

High

10.30

JPMorgan

James Gordon

Neutral

maintain

2025-06-18

Reason

JPMorgan

James Gordon

Price Target

2025-06-18

maintain

Neutral

Reason

JPMorgan analyst James Gordon raised the firm's price target on Grifols to $10.30 from $7.60 and keeps a Neutral rating on the shares.

JPMorgan

Neutral

maintain

2025-06-18

Reason

JPMorgan

Price Target

2025-06-18

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Grifols to EUR 12 from EUR 9.50 and keeps a Neutral rating on the shares.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Grifols SA (GRFS.O) is 9.38, compared to its 5-year average forward P/E of 17.64. For a more detailed relative valuation and DCF analysis to assess Grifols SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

17.64

Current PE

9.38

Overvalued PE

24.14

Undervalued PE

11.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

12.54

Current EV/EBITDA

9.96

Overvalued EV/EBITDA

15.06

Undervalued EV/EBITDA

10.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.43

Current PS

0.94

Overvalued PS

2.12

Undervalued PS

0.73